Helen Higgins

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

Mark T. Drayson, Stella Bowcock, Tim Planche et al. · The Lancet Oncology · 2019 · 160 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation

Leila Rooshenas, Lauren J Scott, Jane Blazeby et al. · Journal of Clinical Epidemiology · 2018 · 98 citations · Full text

Public Health, Health Promotion, Comparative Effectiveness Research +14

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · Journal of Clinical Oncology · 2018 · 70 citations

Medicine, Oncology, Pharmacotherapy +17

An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment

Marcus Jepson, Daisy Elliott, Carmel Conefrey et al. · Journal of Clinical Epidemiology · 2018 · 68 citations · Full text

Public Health, Communication, Evidence-based Practice +13